Washington, DC - Data from 64 HeartMate II (Thoratec) left ventricular assist device (LVAD) patients treated at the Henry Ford Hospital in Detroit suggest that many of the patients implanted with the ...
Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3
ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...
November 17, 2009 (Orlando, Florida) — Advanced heart-failure transplant-ineligible patients with Thoratec's HeartMate II continuous-flow left-ventricular assist device (LVAD) have better-than-even ...
In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...
PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . A new bridge-to-transplant technology is now available for patients in need of a left ventricular assist device.
NEW YORK (April 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate® II LVAS (Left ...
March 12 (UPI) --The HeartMate 3, an update to one of the most widely-used left ventricle assist devices, or LVADs, in the world, showed strong long-term results during a large clinical trial, its ...
Thoratec's HeartMate II left ventricular assist device--Courtesy of Thoratec Thoratec ($THOR) said that two patients died and one suffered a serious injury after they ...
Shares of St. Jude Medical Inc.STJ rose nearly 2.2% yesterday, following the CE Mark approval for HeartMate 3 Left Ventricular Assist System (LVAS) in Europe. The company will start to commercialize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results